Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression.

Spangler JB, Manzari MT, Rosalia EK, Chen TF, Wittrup KD.

J Mol Biol. 2012 Sep 28;422(4):532-44. doi: 10.1016/j.jmb.2012.06.014. Epub 2012 Jun 15.

2.

Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.

Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK.

J Natl Cancer Inst. 2011 Apr 20;103(8):674-88. doi: 10.1093/jnci/djr070. Epub 2011 Mar 11.

PMID:
21398618
3.

KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.

Messner I, Cadeddu G, Huckenbeck W, Knowles HJ, Gabbert HE, Baldus SE, Schaefer KL.

J Cancer Res Clin Oncol. 2013 Feb;139(2):201-9. doi: 10.1007/s00432-012-1319-7. Epub 2012 Sep 27.

PMID:
23015072
4.

Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.

PMID:
23429431
5.

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.

Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL.

Oncogene. 2011 Feb 3;30(5):561-74. doi: 10.1038/onc.2010.430. Epub 2010 Oct 18.

6.

Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.

László L.

Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13.

7.

Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.

Seo Y, Ishii Y, Ochiai H, Fukuda K, Akimoto S, Hayashida T, Okabayashi K, Tsuruta M, Hasegawa H, Kitagawa Y.

Oncol Rep. 2014 May;31(5):2115-22. doi: 10.3892/or.2014.3077. Epub 2014 Mar 11.

PMID:
24626880
8.

Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.

Park JH, Han SW, Oh DY, Im SA, Jeong SY, Park KJ, Kim TY, Bang YJ, Park JG.

Cancer Chemother Pharmacol. 2011 Oct;68(4):1045-55. doi: 10.1007/s00280-011-1586-z. Epub 2011 Feb 22.

PMID:
21340604
9.

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.

Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez-Soler R, Mariadason JM.

Cancer Res. 2008 Mar 15;68(6):1953-61. doi: 10.1158/0008-5472.CAN-07-5659. Erratum in: Cancer Res. 2009 Dec 1;69(23):9156. Cancer Res. 2008 Aug 15;68(16):6859. Soler, Roman Perez [corrected to Perez-Soler, Roman].

10.

Oncogenic RAS simultaneously protects against anti-EGFR antibody-dependent cellular cytotoxicity and EGFR signaling blockade.

Kasper S, Breitenbuecher F, Reis H, Brandau S, Worm K, Köhler J, Paul A, Trarbach T, Schmid KW, Schuler M.

Oncogene. 2013 Jun 6;32(23):2873-81. doi: 10.1038/onc.2012.302. Epub 2012 Jul 16.

PMID:
22797062
11.
12.

Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.

Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A.

Cancer Treat Rev. 2009 May;35(3):262-71. doi: 10.1016/j.ctrv.2008.11.005. Epub 2008 Dec 30. Review.

PMID:
19117687
13.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.

J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.

14.

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouché O, Reid J, Stone S, Penault-Llorca F.

J Clin Oncol. 2009 Dec 10;27(35):5924-30. doi: 10.1200/JCO.2008.21.6796. Epub 2009 Nov 2.

PMID:
19884556
15.

Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.

Montagut C, Iglesias M, Arumi M, Bellosillo B, Gallen M, Martinez-Fernandez A, Martinez-Aviles L, Cañadas I, Dalmases A, Moragon E, Lema L, Serrano S, Rovira A, Rojo F, Bellmunt J, Albanell J.

Br J Cancer. 2010 Mar 30;102(7):1137-44. doi: 10.1038/sj.bjc.6605612. Epub 2010 Mar 16.

16.

The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.

Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M.

Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25. Review.

PMID:
24666267
17.

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients.

Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, Rimassa L, Rossi E, Ligorio C, Di Tommaso L, Holmes AJ, Toschi L, Tallini G, Destro A, Roncalli M, Santoro A, Jänne PA.

Br J Cancer. 2008 Jul 8;99(1):83-9. doi: 10.1038/sj.bjc.6604439. Epub 2008 Jun 24.

18.

Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.

Ruzzo A, Graziano F, Canestrari E, Magnani M.

Curr Cancer Drug Targets. 2010 Feb;10(1):68-79. Review.

PMID:
20088793
19.

A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction.

Tian S, Simon I, Moreno V, Roepman P, Tabernero J, Snel M, van't Veer L, Salazar R, Bernards R, Capella G.

Gut. 2013 Apr;62(4):540-9. doi: 10.1136/gutjnl-2012-302423. Epub 2012 Jul 14.

20.

Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations.

Brandi G, Tavolari S, De Rosa F, Di Girolamo S, Agostini V, Barbera MA, Frega G, Biasco G.

PLoS One. 2012;7(7):e41347. doi: 10.1371/journal.pone.0041347. Epub 2012 Jul 24.

Supplemental Content

Support Center